Back to top

ZINBRYTA (daclizumab) voluntary withdrawal

5 March 2018

As reported in various media outlets over the weekend, pharmaceutical companies Biogen and AbbVie have announced the voluntary worldwide withdrawal for ZINBRYTA ® (daclizumab) for Relapsing multiple sclerosis.

As stated in the official media release (link below), patients currently treated with ZINBRYTA have been asked to contact their healthcare provider with any queries or concerns.

Biogen have specifically advised MS Australia that patients with enquiries about their treatments should speak with their treating Neurologist.

We will update you as more news comes to hand.